Exatecan Antibody-Drug Conjugates with Cathepsin B Linkers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibody-drug conjugates (ADCs) face challenges such as toxicity due to antibody binding in normal tissues and instability of the linker, leading to inadequate safety and efficacy in clinical trials.
Innovation Solution
Development of exatecan derivatives as therapeutic payloads linked to antibodies via specific linker-payload constructs, which are designed to target and deliver topoisomerase I inhibitors preferentially to cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If exatecan is used as a chemotherapeutic agent, then cytotoxic activity is achieved, but high toxicity and lack of efficacy occur at tested doses
Solution Approach 1:
The patent introduces an antibody as an intermediary carrier that selectively delivers exatecan to cancer cells. The antibody binds to specific antigens on cancer cell surfaces, acting as a mediator that concentrates the cytotoxic payload at the target site while preventing widespread distribution to normal tissues, thereby reducing systemic toxicity while maintaining cytotoxic activity.
Solution Approach 2:
The patent segments the drug delivery system into distinct functional components: the antibody portion for targeted delivery, the linker for stable connection, and the exatecan payload for cytotoxic activity. This segmentation allows each component to be optimized independently, with the antibody providing selectivity and the linker ensuring stable transport, thereby improving the therapeutic index.
2Reliability
If ADC linker is used to join antibody and payload, then selective delivery is achieved, but linker instability causes dispersion of cytotoxic payload in normal tissue
Solution Approach 1:
The patent modifies the chemical parameters of the linker to enhance its stability. By selecting linkers with specific chemical structures and bonding characteristics that resist cleavage under physiological conditions, the patent maintains linker integrity during circulation and only releases the payload after internalization by cancer cells, preventing dispersion in normal tissue.
Solution Approach 2:
The patent employs a cleavable linker that is designed to be stable during circulation but can be degraded by specific enzymes (such as cathepsins) inside the cancer cell. This disposable-like approach allows the linker to fulfill its protective function during transport and then be intentionally degraded to release the payload, balancing stability with controlled release.
3Quantity of substance
If exatecan is converted into prodrug form with polyalcohol polymer, then water solubility is improved, but clinical trials still failed due to lack of efficacy or high toxicity
Solution Approach 1:
The patent replaces the polyalcohol polymer prodrug approach with an antibody-based intermediary system. The antibody serves as a targeted delivery vehicle that internalizes exatecan into cancer cells through endocytosis, providing both solubility and selective delivery without the toxicity issues associated with conventional prodrugs. The antibody-mediated mechanism ensures the payload reaches its target effectively.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The proposed exatecan-based drug conjugates aim to enhance safety and efficacy by improving the selective delivery of topoisomerase I inhibitors to cancer cells, potentially overcoming the limitations of existing ADCs.
Implementation Method 1
Topoisomerase I plays a critical role in DNA replication in both normal and diseased conditions (e.g., cancer). As inhibition of topoisomerase I leads to cell death, compounds that bind to and inhibit topoisomerase I may be useful as therapeutic agents.
Implementation Method 2
The binding of its active lactone ring to topoisomerase I inhibits DNA replication, thus causing cell apoptosis.
Implementation Method 3
Antibody-drug conjugates (ADC's) provide a mechanism for selective delivery of small molecule therapeutic payloads to antigen-positive cancer cells
Implementation Method 4
preferential delivery of topoisomerase I inhibitors to diseased tissues through antibody-drug conjugates
Data Source
AI summary
Disclosed herein, in part, are novel exatecan derivatives with novel chemical linkers that include cathepsin B cleavable moieties, and conjugated to targeting antibodies.